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Isosorbide dinitrate and hydralazine combination decreases mortality and hospitalization risk among self-identified black patients with heart failure (HF) and reduced ejection fraction (1,2). The role of this combination therapy is less clear in non-black patients; however, both VasodilatorHeart Failure Trials I and II showed improved ejection fraction and exercise tolerance with this therapy in whites and in blacks (3, 4) . The American College of Cardiology/ American Heart Association HF guidelines give a Class I and IIa indication for this therapy in black and non-black patients with HF and reduced ejection fraction, respectively (5) . Studies have shown attenuated nitric oxide-mediated vasodilation among blacks as compared to non-blacks, with both endothelium-dependent agents (e.g., metacholine) and endothelium-independent agents (e.g., sodium nitroprusside), and also significant imbalance in nitric oxide, superoxide, and their interaction products (6, 7) . Racial differences in HF outcomes and response to therapy may partially be related to this variation, but this hypothesis has yet to be proven conclusively (8) . Decreased synthesis and inactivation of endogenous bioactive nitric oxide is a significant pathogenic mechanism for impaired vasodilation irrespective of race (6, 7, (9) (10) (11) . Exogenous nitrate therapy has beneficial effects for HF treatment at the cellular and hemodynamic level (12, 13) by enhancing endothelium dependent vasodilation (14) and improving systolic function (3, 4) and exercise capacity (15, 16) and inhibiting cardiac remodeling (15) in black and non-black HF patients (Table 1) (8, 12, 13, (17) (18) (19) .
The benefits of nitrates as monotherapy have been shown in animal and human studies to be short-lived due to the development of tolerance and pseudotolerance (20) (21) (22) (23) (24) (25) (26) . However, the studies assessing nitrate tolerance in HF were conducted in an era when the standard HF care was different. The effects of nitrates or hydralazine alone on long-term HF outcomes have not been studied. The rationale for combination therapy includes balanced vasodilation, with nitrates decreasing preload and hydralazine decreasing afterload predominantly (27) . Additionally, hydralazine has antioxidant properties that mitigate nitrate tolerance (23, 24) . However, hydralazine complicates HF therapy with polypharmacy, side effects, and compliance issues (28) . In practice, patients receive lower doses of hydralazine than those proved beneficial in clinical trials (1, 3, 4, 28) . It is unknown whether lower doses provide either meaningful vasodilation or protection against nitrate tolerance.
Angiotensin-converting enzyme (ACE) inhibitors are the standard of care for treating HF with low ejection fraction. In addition to favorable neurohormonal modulation, ACE inhibitors are vasodilators, possess antioxidant properties (29, 30) , and prevent nitrate tolerance. Concurrent ACE inhibitor therapy can therefore potentially obviate hydralazine, improving nitrate use in HF.
Nitrate Tolerance and Pseudotolerance
Nitric oxide (NO) affects endothelial function and vascular tone and has beneficial downstream myocardial effects (8, 11, 31, 32) . Its functionality depends on the balance between NO and reactive oxygen species (8, 33) . Activation of the renin-angiotensin-aldosterone system (RAAS) in HF results in decreased NO bioavailability and antioxidant reserve, as well as an increase in oxidative stress and reactive oxygen species, such as superoxide, culminating in endothelial dysfunction and free radical injury, which worsens HF (10, 11, 25, 31) . Pharmacological supplementation of NO improves hemodynamics (26) . However, 24 to 72 h of continuous nitrate therapy can lead to tolerance and pseudotolerance (21, 22, (24) (25) (26) 34) . Pathophysiology of pseudotolerance. After 24 to 48 h of nitrate therapy, reflex increases in plasma renin activity, angiotensin II, norepinephrine, and arginine vasopressin may lead to adverse vascular and volume effects, increasing intravascular volume and leading to reversal of nitroglycerin hemodynamic benefitsda phenomenon known as pseudotolerance (21, 22, 25, 35, 36) (Fig. 1) . Packer et al. (21) noted an increase in plasma renin activity after 48 h of continuous nitroglycerin infusion compared to the near-baseline levels seen after intermittent dosing (12.9 AE 4.8 ng/ml/h vs. 7.7 AE 3.0 ng/ml/h; p < 0.01). This was associated with an increase in body weight related to sodium retention (21 (22) . This was not seen with intermittent nitroglycerin exposure. Pathophysiology of tolerance. Neurohormonal activation due to nitrate therapy stimulates superoxide production. This is mediated through angiotensin II, resulting in elevated superoxide generation, inactivating the vasodilatory effect of NO (17, 24, 33, 37) . A sulfhydryl donor must reduce nitrates to activate guanylate cyclase-mediated smooth muscle relaxation (37) (38) (39) . Continuous nitrate exposure leads to a depletion of sulfhydryl, limiting its vasodilatory capabilities (37) . Interestingly, plasma nitrate concentrations are higher with shortterm than with long-term therapy, even at the same dose (37, 40) . This combination of decreased functionality and increased inactivity leads to reversal of the physiologic benefits of nitrate and to the development of tolerance (21, 26, 37) .
Several studies have assessed the hemodynamic tolerance to nitrates in patients with HF (21, 22, 25, 26, (41) (42) (43) (44) PM and starting again at 12 AM on the following day (allowing a 12-h nitrate washout interval after the third dose). All groups showed reduction in filling pressure following the first dose, but early attenuation was seen in those receiving more frequent dosing. The 8-h regimen demonstrated less tolerance with preserved hemodynamic response to each dose. Nonetheless, the effect of each dose was shortlived, with a return of pulmonary wedge pressures to baseline 2 to 4 h after each dose. The overall duration of favorable effect was no more than 12 of the 30-h study period. A thrice-daily regimen resulted in marked attenuation of response after the third dose, with complete restoration following 12-h washout.
Packer et al. (21) studied intravenous nitroglycerin for 48 h continuously or 2 12-h infusions followed by a 12-h nitroglycerin-free period. Initial infusion decreased systemic vascular resistance and left ventricular filling pressure in both groups, but after 48 h, the continuous infusion showed marked attenuation of response to near-baseline levels. These changes were not observed with intermittent infusion. In another study, 60 mg/24 h nitroglycerin patch in 23 HF patients showed plasma nitroglycerin level to rise from 0.04 AE 0.12 ng/ml at baseline to near-peak levels after 2 h (7.43 AE 7.21 ng/ml). Pulmonary wedge pressure fell at 4 h (22 AE 7 mm Hg to 14 AE 5 mm Hg; p < 0.01). Despite persistently high nitroglycerin levels, pulmonary wedge pressure was no longer significantly reduced (20 AE 9 mm Hg) after 18 h of continuous therapy (44) .
Hydralazine Use and Nitrate Tolerance
Combination hydralazine-nitrate therapy began in an effort to create an oral regimen with balanced arterial and venous dilation similar to that with nitroprusside, which is associated with increased cardiac output and decreased filling pressures (27, 45) . Later, hydralazine was demonstrated to lower NADH-oxidase levels and superoxide production, counteracting tolerance (2, 24, 33, 45) . Munzel et al. (24) studied untreated rabbits and those treated with nitroglycerin, hydralazine, or both. The nitroglycerin group manifested a greater-than-twofold increase in vascular superoxide production that decreased with hydralazine (1,121 AE 72 counts/mg/min vs. 459 AE 59 counts/mg/min; p < 0.05). Gogia et al. (46) studied 28 HF patients randomized to nitroglycerin alone or with hydralazine. Compared with the initial response, significant attenuations in mean pulmonary artery pressure (27 AE 4 mm Hg vs. 10 AE 3 mm Hg; p < 0.05) and pulmonary wedge pressure (40 AE 4 mm Hg vs. 16 AE 4 mm Hg; p < 0.05) were seen with nitroglycerin alone at 24 h. Oral hydralazine prevented tolerance, resulting in a persistent effect on pulmonary artery and wedge pressures throughout the 24-h study period (31 AE 3 mm Hg vs. 27 AE 4 mm Hg, p ¼ 0.13 and 37 AE 4 mm Hg vs. 34 AE 6 mm Hg, p ¼ 0.40, respectively).
Problems With Hydralazine Therapy
Despite known benefits, multiple studies have found very low rates of hydralazine-isosorbide dinitrate use in HF Gupta et al.
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Nitrate Therapy for Heart Failure 185 patients, ranging from 2.6% to 7%, depending on race and severity of disease (28, 47, 48) . Thrice-daily dosing of hydralazine hinders compliance. Isosorbide dinitrate is dosed similarly; however, unlike hydralazine, other long-acting nitrate formulations exist that may allow less frequent dosing (8) . At this time, it is unclear whether these longeracting formulations would provide the same benefit as shortacting nitrates, warranting further study. Increases in RAAS and sympathetic nervous system activity in animals (24, 49) , and increase in heart rate with hydralazine in humans (50), have been described. Dizziness and nausea are known side effects with hydralazine. Packer et al. (51) noted an increase in hemodynamic and ischemic complications in 23% of the study subjects when using hydralazine alone compared with nitroprusside. Whether these complications were related to the cumulative daily dose, to the starting dose, or to the titration protocol needs further consideration. In a post hoc analysis of the African American Heart Failure Trial, Anand et al. (52) cited only a modest reduction in blood pressure with the combination therapy in those with a baseline systolic blood pressure 112 mm Hg. However, in clinical practice, if doses used are lower than those given in the African American Heart Failure Trial, then whether such lower doses provide either a hemodynamic or a nitratetolerance benefit is not known (53) .
RAAS and Nitrate Tolerance
After 24 h of nitroglycerin use, angiotensin II type 1 (AT1) receptor expression and vascular ACE activity decrease and vascular constriction to angiotensin II is depressed without loss of nitroglycerin vasodilator potency; however, within 3 days of continuous exposure, relaxation to nitroglycerin is blunted (25) . This was associated with an increase in AT1 receptor mRNA expression, a return of ACE activity to baseline, and increased constriction to angiotensin II. There was a decrease in vascular superoxide dismutase activity and a doubling of superoxide production. Concurrent treatment 
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with losartan normalized superoxide levels in a dosedependent manner and prevented tolerance (25) . Captopril has the added benefit of containing a sulfhydryl group that can replete endothelial sulfhydryl stores, allowing conversion of nitrates to NO versus superoxide (11, 12, 54) . Several studies have shown prevention of nitrate tolerance by ACE inhibitors, related to inhibiting conversion of angiotensin I to angiotensin II (18, 55, 56) . Although tolerance and pseudotolerance are often viewed as separate pathways, the overlapping importance of RAAS activation and the benefit of RAAS modulators raise the likelihood that the two may be closely inter-related.
Effect of Concomitant ACE Inhibitor and Nitrate Therapy
Hemodynamic properties. ACE inhibitors allow continued hemodynamic response to nitroglycerin therapy despite increased plasma renin activity (Table 2) (11, 12, 15, 18, 19, 54, 55, (57) (58) (59) (60) (61) . In 11 HF patients receiving captopril, isosorbide dinitrate q6h led to significant lowering of right atrial pressure (from 13 AE 6 mm Hg to 9 AE 4 mm Hg), pulmonary artery pressure (from 38 AE 7 mm Hg to 29 AE 9 mm Hg), and pulmonary wedge pressure (from 24 AE 6 mm Hg to 15 AE 7 mm Hg) after 1 h of nitrate dose; these benefits persisted for the 24-h study period (12). Katz et al. (61) randomized 34 subjects to enalapril 10 mg b.i.d., captopril 25 mg t.i.d., or placebo. Response to sublingual nitroglycerin was assessed with forearm plethysmography at: 1) baseline and 2) after 4 days of ACE inhibitor or placebo administration; 3) 2 h after 10-mg/24 h nitroglycerin patch administration; and 4) 74 h after nitroglycerin patch administration. Nitrate response remained unchanged after 2 h of nitroglycerin treatment in all groups. After 74 h of nitroglycerin use, the venodilator response to sublingual nitroglycerin was reduced by 40% in the placebo group, 10% in the enalapril group, and 2% in the captopril group (p < 0.01 vs. placebo) (61) . In patients with coronary disease, two studies have shown that ACE inhibitors prevent tolerance after 24 to 48 h of continuous nitroglycerin use, with an increase in cardiac index and reductions in systemic vascular resistance, arterial pressure, and pulmonary wedge pressure (18, 55) . Similar benefit has been reported with losartan and nitroglycerin use (59) . Exercise tolerance. Examining the effects of 50-to 100-mg transdermal nitroglycerin versus placebo given daily for 12 h in 29 HF patients, one study showed that exercise time improved when nitroglycerin was added to captopril therapy whereas no change was seen with placebo (15) . Exercise time 8 h after nitroglycerin application at 3 months was significantly longer. Left ventricular function. The same study (15) also showed that nitroglycerin therapy with captopril significantly reduced left ventricular end-diastolic (-2.1 AE 0.1%; p < 0.05) and end-systolic dimensions (-3.2 AE 1.3%; p < 0.05) and augmented fractional shortening (24.7 AE 10.5%; p < 0.03); these effects were not observed with placebo. Endothelial function. In one study, the effect of ACE inhibitor with and without a sulfhydryl group on platelet cGMP and forearm blood flow was measured before and 5 min after administration of sublingual nitroglycerin in HF patients at: 1) baseline; 2) 1 week after 10-mg/day nitroglycerin patch; 3) 1 week after captopril 37.5 mg/day and 10-mg/day nitroglycerin patch; and 4) 1 week after enalapril 5 mg/day and 10-mg/day nitroglycerin patch. Increases in cGMP level and forearm blood flow after sublingual nitroglycerin were lower with nitroglycerin alone than baseline, but captopril and enalapril maintained the increase in platelet cGMP and forearm blood flow (54). Negative studies. Not all studies with ACE inhibitor have shown mitigation of nitrate tolerance. Benazepril was ineffective in maintaining a hemodynamic response with nitroglycerin therapy in healthy subjects (57) . Two studies showed no hemodynamic benefit with captopril and nitroglycerin use in HF (19, 58) . Similarly, some studies with hydralazine have also not shown mitigation of nitrate tolerance either (53, 62) .
Vasodilation With ACE Inhibitors Versus Hydralazine
One rationale for hydralazine use in HF is its vasodilator effects (63 ; p < 0.001) with an increase in cardiac index (2.1 AE 0.5 l/min/m 2 vs. 2.5 AE 0.5 l/min/m 2 ; p < 0.001) with captopril (64) . In addition, captopril decreased left ventricular and right atrial pressures and heart rate. In those treated with hydralazine, heart rate increased (64) . Decreases in pulmonary pressures have also been reported with captopril (65) . Other studies have also shown vasodilator effects with long-term ACE inhibitor use as well (66) (67) (68) .
Other Heart Failure Therapies and Nitrate Tolerance Several animal and human studies have examined the impact of angiotensin receptor blockers, beta-blockers, and aldosterone antagonists on nitrate tolerance (56, 60, (69) (70) (71) (72) (73) . Kurz et al. (25) demonstrated a reduction in superoxide production with losartan. In patients with coronary vasospasm, candesartan plus nitrates showed a decrease in oxidative stress and an increase in brachial artery diameter as 
